 |
인쇄하기
취소
|
Peptron wins Australia patent for once-weekly anti-diabetic agent
Peptron Inc. says it recently won Australia patent for sustained release formulation of exenatide (codename: PT302). The firm won a Korean patent in February 2008.
Exenatide is the first and only approved incretin mimetic, a class of drugs for the treatment of type 2 diabetes. Exenatide is approved in the European Union as adjunctive therapy to improve blood sugar control in patients with ty...
Exenatide is the first and only approved incretin mimetic, a class of drugs for the treatment of type 2 diabetes. Exenatide is approved in the European Union as adjunctive therapy to improve blood sugar control in patients with ty...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.